.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,105,486

« Back to Dashboard

Claims for Patent: 7,105,486

Title:Abuse-resistant amphetamine compounds
Abstract:The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Inventor(s): Mickle; Travis (Charlottesville, VA), Krishnan; Suma (Blacksburg, VA), Bishop; Barney (Annandale, VA), Lauderback; Christopher (Blacksburg, VA), Moncrief; James Scott (Blacksburg, VA), Oberlender; Rob (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA)
Assignee: New River Pharmaceuticals Inc. (Radford, VA)
Application Number:10/858,526
Patent Claims: 1. A method for treating a patient having attention deficit hyperactivity disorder, comprising orally administering to the patient in need thereof a pharmaceutically effective amount of L-lysine-d-amphetamine, or salts thereof.

2. The method of claim 1, wherein said step of orally administering comprises administering a tablet, a capsule, a caplet, an oral solution, or an oral suspension.

3. The method of claim 1, wherein the L-lysine-d-amphetamine is administered in the form of a salt.

4. The method of 3, wherein the salt is a mesylate salt of L-lysine-d-amphetamine.

5. The method of claim 3, wherein the salt is a hydrochloride salt of L-lysine-d-amphetamine.

6. The method of any one of claims 3 5, wherein said step of orally administering comprises administering a tablet, a capsule, a caplet, an oral solution, or an oral suspension.

7. The method of claim 1, comprising administering a dosage form containing from about 5 mg to about 500 mg of the L-lysine-d-amphetamine or a salt thereof.

8. The method of claim 7, comprising administering a dosage form containing from about 10 mg to about 250 mg of the L-lysine-d-amphetamine or a salt thereof.

9. The method of claim 6, comprising administering a dosage form containing from about 5 mg to about 500 mg of the L-lysine-d-amphetamine or a salt thereof.

10. The method of claim 6, comprising administering a dosage form containing from about 10 mg to about 250 mg of the L-lysine-d-amphetamine or a salt thereof.

11. The method of claim 6, wherein the L-lysine-d-amphetamine or salt thereof is in an amount sufficient to provide a therapeutically bioequivalent AUC when compared to amphetamine alone, but does not provide a C.sub.max which results in euphoria.

12. The method of claim 7, wherein the dosage form is administered one or more times per 24-hour period.

13. The method of claim 8, wherein the dosage form is administered one or more times per 24-hour period.

14. The method of claim 9, wherein the dosage form is administered one or more times per 24-hour period.

15. The method of claim 10, wherein the dosage form is administered one or more times per 24-hour period.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc